After one of the most dramatic sell-offs in recent ASX healthcare history, Cochlear Ltd (ASX: COH) shares may finally be showing signs of life.
The hearing implant leader remains down around 60% year to date, but it has quietly staged a comeback in recent weeks, climbing 8.5% over the past month. At the time of writing, Cochlear shares trade at $104.45.
So, is this modest recovery the start of something bigger?
Here are three reasons investors may want to consider buying the healthcare stock in June.
Image source: Getty Images
The bad news may already be priced in
It's worth remembering just how brutal April was for shareholders.
Most of the pain arrived on 22 April following the release of a decidedly unwelcome trading update.
Cochlear shares closed down 40.7% in a single session after the company reported falling demand for its implants in developed markets. Management also flagged cancellations and delivery delays in the Middle East due to the ongoing conflict.
The update forced the company to slash its FY2026 underlying net profit guidance to between $290 million and $330 million, down from its prior guidance range of $435 million to $460 million.
The downgrade shocked investors. But after such a severe reset in expectations, the market may have already priced in much of the near-term weakness.
Cochlear remains the industry leader
While earnings expectations have changed, Cochlear's competitive position has not.
The company still commands roughly 50% of the global cochlear implant market, making it the clear industry leader.
Even more importantly, the long-term growth opportunity for Cochlear shares remains enormous. The addressable market exceeds six million patients in developed markets alone, yet penetration sits at only around 3%.
Over more than four decades, Cochlear has invested heavily in research and development, building a product moat that competitors have struggled to replicate.
With ageing populations, growing awareness of hearing loss, and continued adoption of implantable hearing technology, the long-term demand outlook remains compelling.
Analysts and management see a brighter future
Broker sentiment has become increasingly constructive following the sell-off.
Both Jarden and Wilsons Advisory believe the market reaction has been excessive, with each seeing upside of more than 60% in Cochlear shares over the next 12 months.
Management also continues to argue that the recent volume weakness is temporary rather than structural.
CEO Dig Howitt stated the following in the company's April trading update:
The clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment. Cochlear implants are also associated with a lower incidence of dementia, with dementia rates lower than in hearing aid users and comparable to those with normal hearing.
Those comments highlight an important point. The factors that drove Cochlear's long-term growth story before April's shock downgrade remain firmly in place today.
If demand stabilises and delivery disruptions ease, investors buying Cochlear shares after the sell-off could be well positioned to benefit from a recovery in both earnings expectations and market sentiment.
